2005
DOI: 10.1007/s00280-004-0924-9 View full text |Buy / Rent full text
|
|

Abstract: Hypersensitivity reaction (HSR) is still a major concern during cancer chemotherapy with paclitaxel. In the present study, we investigated retrospectively the incidence of HSRs to paclitaxel and the risk factors in 105 patients (553 courses) who received adjuvant chemotherapy (paclitaxel and carboplatin) for ovarian cancer. Moderate to severe HSRs that led to cessation or discontinuation of the chemotherapy, including respiratory distress and hypotension, were observed in 14 patients (13.3%) and 16 courses (2.… Show more

Help me understand this report

Search citation statements

Order By: Relevance
Select...
3
1
1
22
2

Year Published

2006
2006
2014
2014

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

1
22
2
Order By: Relevance
“…It has been reported that the incidence rate of paclitaxel-induced HSRs is 8-14% in patients with ovarian cancer. 2,3,17,18 Consistent with these data, the incidence of grade 2 HSRs to paclitaxel observed in the present study was 11.9%, which was also comparable to those reported in our previous study, 5 in which 14 (13.3%) of 105 patients with ovarian cancer who undertook postoperative paclitaxel and carboplatin combination chemotherapy showed grade 2 HSRs, regardless of the presence of premedication with glucocorticoid, and histamine H 1 and H 2 antagonists. However, it is noteworthy that no signs of HSRs were observed after paclitaxel infusion, when pretreated with pemirolast in combination with the conventional premedication regimen.…”
Section: Discussionsupporting
See 1 more Smart Citation
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1.2b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 14 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 130,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…It has been reported that the incidence rate of paclitaxel-induced HSRs is 8-14% in patients with ovarian cancer. 2,3,17,18 Consistent with these data, the incidence of grade 2 HSRs to paclitaxel observed in the present study was 11.9%, which was also comparable to those reported in our previous study, 5 in which 14 (13.3%) of 105 patients with ovarian cancer who undertook postoperative paclitaxel and carboplatin combination chemotherapy showed grade 2 HSRs, regardless of the presence of premedication with glucocorticoid, and histamine H 1 and H 2 antagonists. However, it is noteworthy that no signs of HSRs were observed after paclitaxel infusion, when pretreated with pemirolast in combination with the conventional premedication regimen.…”
Section: Discussionsupporting
“…The HSRs to paclitaxel are characterized by flushing, chest discomfort, respiratory distress and pulmonary edema, [1][2][3][4] and the incidence is particularly high in patients with ovarian cancer who undertook postoperative chemotherapy containing paclitaxel. 5 To avoid the HSRs, premedication containing histamine H 1 and H 2 antagonists in combination with glucocorticoids is always prescribed, [6][7][8][9][10] although the preventive effect is by no means complete. However, there has been no direct evidence suggesting that the HSRs to paclitaxel are mediated by the release of histamine from mast cells or basophils.…”
mentioning
“…Our study, on the other hand, included different chemotherapy regimens for gynecologic pelvic cancers, and while these studies are not completely comparable, our data did not confirm previous results. In our study, postmenopausal status appeared to have a protective OR for HR (a causal link between the oscillations of sex hormones and the overall allergic response has recently been suggested by De Oliveira et al [21]), while Sendo et al [20], with a similar number of cases, had the opposite results: this can be explained by the small number variability. In our cohort only 10 patients were not postmenopausal.…”
Section: Discussioncontrasting
“…Sendo et al [20] found five HR risk factors for hypersensitivity to paclitaxel: a history of dermal allergic reactions, respiratory dysfunction, obesity, postmenopausal and non-drinker status, in 14 cases of HR. Our study, on the other hand, included different chemotherapy regimens for gynecologic pelvic cancers, and while these studies are not completely comparable, our data did not confirm previous results.…”
Section: Discussionmentioning
“…For both docetaxel and paclitaxel, a history of mild skin reactions during earlier treatments; the presence of respiratory dysfunction, overweight, or obesity; and menopausal or postmenopausal status have also been reported as risk factors [21][22][23] .…”
Section: 22mentioning